\
&
Contact us
\
&
Contact us
Starts in 1 month from now
LocationStrasbourg, France
KETs 2025 is a one-day EU Brokerage Event dedicated to exploring Key Enabling Technologies (KETs) and their pivotal role in driving technological innovation across various industries. The event will feature keynote speeches, panel discussions, and networking sessions, focusing on the latest advancements in KETs and their applications in sectors such as healthcare, manufacturing, and energy.
The conference is designed for industry professionals, researchers, policymakers, and investors interested in the development and commercialization of KETs. It offers a platform for participants to exchange ideas, discover collaboration opportunities, and stay updated on emerging trends in technological innovation.
1 day, 1 Plenary session, more than 10 Thematic workshops with pitching sessions, and B2B meetings. Focus on Manufacturing and Production & Buildings, Circular Economy, Raw Materials & Steel, Advanced Materials, Battery Value Chain and Hydrogen, Digital, AI/Data/Robotics, Photonics & Quantum Technology.
For more information on the event agenda, speakers, and registration details, please visit the official event page.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
